Shaping the Future of Regenerative Medicine
Breast cancer is the most common cancer among women, with approximately 2.3 million new cases each year—affecting 1 in 8 women. In Europe, 60% of women undergoing mastectomy opt for reconstructive breast surgery, but existing methods are often complex and require multiple surgeries or treatments.
In response to the critical need for safer, more effective, and natural breast reconstruction treatments following breast cancer treatment, 4Tissue's hydrogel tissue mimic technology promotes natural cell regeneration. Unlike traditional implants or flap surgeries, 4Tissue's minimally invasive, injectable solution supports the body's natural tissue regeneration process, delivering durable and predictable results.
Natural
Restores
natural breast tissue with the body's own material, enhanced by a bioresorbable
hydrogel, delivering a soft, natural look and feel without synthetic implants.
Bio-Compatible and Safe
Our hydrogel tissue mimic supports natural cell regeneration and becomes part of the body's metabolism, minimizing risks of rejection and complications associated with synthetic implants.
Leaving no visible scar
With small-needle injections, there's minimal to no visible scarring, making it an ideal solution to provide a natural and authentic result.
One Treatment, lasting Results
Our bioresorbable tissue mimic supports the creation of a solid, body-own tissue for a natural, durable enhancement in a single treatment.
Developing solutions to overcome the limitations of current cell-based therapies
Low cell survival is a major obstacle in breast tissue replacement, often resulting in multiple procedures and unnatural shaping. Cells struggle to survive due to injection damage, leakage, harsh tissue environments, lack of attachment, and nutrient starvation.
Our bioresorbable hydrogel transforms this process by protecting and anchoring cells, providing a nurturing environment, and support natural blood vessel growth to supply essential nutrients. As the hydrogel resorbs, it leaves healthy, natural tissue, offering a safer and more predictable alternative to traditional methods.
About Us
4Tissue is a biotech company at the forefront of regenerative medicine, utilizing advanced bio-interactive hydrogels to transition from cells to tissue engineering.
Founded through a collaboration between Prof. Phillip Blondeel, a global leader in plastic and reconstructive surgery, and Prof. Dr. Sandra Van Vlierberghe, an expert in polymer chemistry, 4Tissue is a spin-off from Ghent University (UGent), Ghent University Hospital (UZGent), and the Vrije Universiteit Brussel (VUB).
The company develops natural and minimally invasive treatments for tissue reconstruction and regeneration. By harnessing cutting-edge science and a multidisciplinary team of experts, 4Tissue aims to shape the future of regenerative medicine and improve patient outcomes worldwide.
Meet us at one of the coming conferences
"At 4Tissue, we are focused on transforming our scientific breakthroughs into real-world solutions that will revolutionize tissue engineering and regenerative medicine. By advancing our goals through continuous collaboration, resilience, and perseverance, we are determined to make a lasting impact on healthcare by bringing innovative, natural alternatives to the market."
Benoit Moreaux, PhD, CEO, 4Tissue